Milne Heather Carrier, Vallerand April Hazard
Wayne State University, 5557 Cass Avenue, Detroit, MI 48202, USA.
Prog Cardiovasc Nurs. 2009 Sep;24(3):90-5. doi: 10.1111/j.1751-7117.2009.00041.x.
More than 6 million people in the United States are affected by chronic angina. On January 27, 2006, the US Food and Drug Administration (FDA) approved a new medication for the treatment of chronic stable angina called ranolazine (Ranexa). This is the first angina drug approved by the FDA in over a decade. The unique thing about this drug is that it falls into a new class of therapies in that it works at the level of cellular metabolism in decreasing demand on the cardiac tissue. There are many factors to consider when prescribing this medication including past studies, dosing, and education. There is also evidence that this drug may also benefit diabetic patients with glycemic control.
美国有超过600万人受到慢性心绞痛的影响。2006年1月27日，美国食品药品监督管理局（FDA）批准了一种名为雷诺嗪（Ranexa）的用于治疗慢性稳定型心绞痛的新药。这是FDA十多年来批准的首个抗心绞痛药物。这种药物的独特之处在于它属于一类新的治疗方法，即它在细胞代谢水平发挥作用，减少心脏组织的需求。在开这种药时需要考虑许多因素，包括以往的研究、剂量和患者教育。也有证据表明这种药物可能对糖尿病患者的血糖控制有益。
